Takeda’s Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial

Also Read

• Parliamentary Committee Mandates Comprehensive Capital Market Overhaul to Strengthen Regulatory Framework and Investor Protection
• Israeli Prime Minister Says Diverted Flydubai Flight Was Not a Kidnapping
• Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial
• Egyptian President El-Sisi Confirms $20 Billion Loss in Suez Canal Revenue Amid Regional Instability